Differentiated Thyroid Cancer clinical trials

Explore recruiting differentiated thyroid cancer clinical trials.

Recruiting differentiated thyroid cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Differentiated Thyroid Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

[18F]Tetrafluoroborate PET/CT for the Detection of Differentiated Thyroid Cancer: A Phase II Imaging Study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

Romania, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphy

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

REGOMUNE : A phase I/II study of Regorafenib plus Avelumab in solid tumors

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Differentiated Thyroid Cancer trials by city

Differentiated Thyroid Cancer clinical trials

Recruiting differentiated thyroid cancer studies right now

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients

Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Adjuvant Radiotherapy in High Risk Locally Advanced DTC

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma